Status:
RECRUITING
Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Safety Issues
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This is a randomized study to evaluate the safety and feasibility of early de-escalation of empirical antibiotics treatment in neutropenic fever patients undergoing hematopoietic stem cell transplanta...
Detailed Description
This is a randomized study to evaluate the safety and feasibility of early de-escalation treatment of empyrical antibiotics treatment in neutropenic fever patients undergoing hematopoietic stem cell t...
Eligibility Criteria
Inclusion
- Age ≥18，patients undergo hematopoietic stem cells
- Patients with neutropenic fever: T≥38.5°C once or T≥38°C twice a day with ANC \<0.5x109/L or predicted to be \<0.5x109/L in 24 \~48 hours；
- Patients achieved afebrile （T\<37.5°C）for at least 72 hours；
- Inform consent given
Exclusion
- Patients with neutropenic fever with documented blood stream infection, skin and soft tissue infection, pneumonia and catheter associated infection.
- Patients with septic shock
- Levofloaxin allergy or contra-indication
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04270786
Start Date
January 1 2020
End Date
June 30 2026
Last Update
February 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, Shanghai Municipality, China, 200025